Table 1.
Baseline clinical characteristics
| Clinical Characteristics | Overall (n = 100) | RVdys + (n = 32)* | RVdys- (n = 68) | p |
|---|---|---|---|---|
| Age (years) | 67.8 ± 10.0 | 69.9 ± 10.1 | 66.8 ± 9.9 | 0.16 |
| Male | 80% (80) | 87.5% (28) | 76.5% (52) | 0.20 |
| Body surface area | 1.9 ± 0.2 | 1.9 ± 0.2 | 2.0 ± 0.2 | 0.69 |
| Heart rate | 66.8 ± 14.6 | 69.9 ± 14.5 | 65.4 ± 14.6 | 0.18 |
| Systolic blood pressure | 121.9 ± 17.0 | 123.5 ± 12.5 | 121.2 ± 18.7 | 0.53 |
| Diastolic blood pressure | 68.8 ± 10.4 | 68.3 ± 10.4 | 69.0 ± 10.5 | 0.78 |
| CV risk factors | ||||
| Hypertension | 79% (79) | 68.8% (22) | 85.1% (57) | 0.06 |
| Hypercholesterolemia | 76% (76) | 68.8% (22) | 80.6% (54) | 0.20 |
| Diabetes mellitus | 50% (50) | 62.5% (20) | 44.8% (30) | 0.10 |
| Tobacco use | 61% (61) | 65.6% (21) | 59.7% (40) | 0.57 |
| Family history CAD | 24% (24) | 21.9% (7) | 25.4% (17) | 0.70 |
| Prior myocardial infarction | 54% (54) | 59.4% (19) | 52.2% (35) | 0.51 |
| Cardiovascular medications | ||||
| Loop diuretic | 42% (42) | 62.5% (20) | 32.8% (22) | 0.005 |
| ACEI/ARB | 60% (60) | 75.0% (24) | 53.7% (36) | 0.04 |
| Aspirin | 87% (87) | 87.5% (28) | 88.1% (59) | 0.94 |
| Thienopyridine | 40% (40) | 46.9% (15) | 37.3% (25) | 0.37 |
| Beta-blocker | 78% (78) | 81.3% (26) | 77.6% (52) | 0.68 |
| Cardiovascular symptoms | ||||
| NYHA Class (1/2/3/4) | 55% (55) /24% (24) /11% (11) /6% (6) | 30.0% (9) /36.7% (11)/ 16.7% (5) /16.7% (5) | 69.7% (46) /19.7% (13)/ 9.1% (6) /1.5% (1) | < 0.001 |
| Dyspnea | 59% (59) | 82.8% (24) | 59.3% (35) | 0.03 |
| Angina | 49% (49) | 62.1% (18) | 52.5% (31) | 0.40 |
| Prior coronary revascularization | ||||
| PCI | 57% (57) | 62.5% (20) | 55.2% (37) | 0.49 |
| CABG | 32% (32) | 34.4% (11) | 31.3% (21) | 0.76 |
| PCI or CABG | 77% (77) | 81.3% (26) | 76.1% (51) | 0.57 |
Bold values identify a significance of p < 0.05